Study Title
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial
Study Details
Description:
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Sponsor:
Clarity PharmaceuticalsContacts:
Clarity Pharmaceuticals (Clarity Clinical)clinicaltrials@claritypharmaceuticals.com
+61 0 2 9209 4037
Government Study Link:
NCT04023331 - Click here to see study onClinicalTrials.gov
Inclusion
- • Known high-risk neuroblastoma OR previously intermediate-risk neuroblastoma that has relapsed
- • Karnofsky or Lansky performance status ≥50;
- • Adequate liver function
- • Adequate renal function
Exclusion
- • Any other active malignancy, or a history of prior malignancy within the past 3 years;
- • Participants with disease of any major organ system that would compromise their ability to tolerate therapy
- • History of cardiac failure
- • Participants who are on hemodialysis
- • Any medical condition which the Investigator feels may interfere with the procedures or evaluations of the study
Patient Education
Patient Education Not Yet Provided
Publications
Publications Not Yet Provided
Locations
United States
